Clinical trial · Observational
Epigenetic Profiling and Liquid Biopsy: Perspectives for Personalized Medicine in Meningioma Patients - MIND
Epigenetic Profiling and Liquid Biopsy: Perspectives for Personalized Medicine in Meningioma Patients
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Meningiomas are the most common primary intracranial tumors. Current treatment relies on surgical resection and radiotherapy, but molecular predictors for recurrence are lacking. This study aims to investigate epigenetic features, specifically histone post-translational modifications (PTMs) and DNA methylation, to stratify patients. The study involves a retrospective cohort to define an epigenetic signature and a prospective cohort to validate it in tissues and liquid biopsies (plasma/EVs).
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Meningioma | Meningioma | ONTOLOGY_EXACT | 0.90 |
| Meningioma of Brain | — | UNRESOLVED | — |
Interventions
Interventions (0)
Data not yet available
Design
Arms and outcomes
Arms (2)
- label
- Retrospective Cohort
- description
- 150 patients operated for non-recurrent meningioma between 2008 and 2016.
- label
- Prospective Cohort
- description
- 60 patients diagnosed with meningioma recruited prospectively.
Primary outcomes (1)
- measure
- Definition of a novel epigenetic signature based on MS-profiling
- timeFrame
- Months 1-12
- description
- Identification of histone post-translational modifications (PTMs) patterns in FFPE tissue samples capable of classifying tumor recurrence.
Secondary outcomes (4)
- measure
- Validation of epigenetic signature in prospective tissues
- timeFrame
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: Inclusion Criteria (Retrospective \& Prospective): * Patient aged 18 years or older. * First diagnosis of uni-focal meningioma of the convexity. * Macroscopical total resection (Simpson 1-3). (Retrospective only): * Surgery performed between 2007 and 2016; * availability of FFPE sample and medical records. Exclusion Criteria: * Genetic syndromes. * Diffuse Meningeal Meningiomatosis. * Patients who underwent experimental treatment in neo-adjuvant setting. (Prospective only): * Previous surgical/medical treatment for another meningioma; * positive oncological history (e.g., breast cancer).
References
Publications (0)
Data not yet available